Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: June 13, 2026
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.
Journal: Gynecologic oncology
Published: April 12, 2026
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: May 20, 2025
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 28, 2025
Hypercalcemia of Malignancy: An Atypical Presentation of Endometrial Carcinoma.
Journal: Cureus
Published: September 19, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: March 08, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Journal: Lancet (London, England)
Published: December 15, 2023
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Journal: Gynecologic oncology
Published: October 20, 2023
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Journal: Future oncology (London, England)
Published: June 19, 2023
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Journal: Gynecologic oncology
Published: June 17, 2023
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.
Journal: Therapeutic advances in medical oncology
Published: June 10, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 15, 2022
Last Updated: 09/26/2026